This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

This study has been completed.
Information provided by (Responsible Party):
CASI Pharmaceuticals, Inc. Identifier:
First received: April 11, 2008
Last updated: January 26, 2016
Last verified: January 2016
A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.

Condition Intervention Phase
Advanced Cancer Drug: ENMD-2076 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

Further study details as provided by CASI Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Safety and tolerability of ENMD-2076 [ Time Frame: Throughout study treatment ]

Secondary Outcome Measures:
  • Plasma PK [ Time Frame: Throughout study treatment ]
  • Evidence of benefit (tumor response, clinical benefit, or tumor marker improvement, if appropriate) [ Time Frame: Throughout study treatment ]

Enrollment: 67
Study Start Date: April 2008
Study Completion Date: June 2012
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: ENMD-2076
Capsules, daily dosing in 28 day cycles
Experimental: 2
Advanced cancer, excluding patients with colorectal or ovarian cancers
Drug: ENMD-2076
Capsules, daily dosing in 28 day cycles
Experimental: 3
Recurrent or resistant epithelial ovarian cancer
Drug: ENMD-2076
Capsules, daily dosing in 28 day cycles
Experimental: 4
Colorectal cancer patients who have progressed and/or failed on irinotecan- and oxaliplatin-based regimens
Drug: ENMD-2076
Capsules, daily dosing in 28 day cycles


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have histologic proof of advanced cancer that has progressed after treatment and has no standard therapy that is curative or provides clinical benefit.
  • Meet the modified RECIST Criteria or have disease that can be followed for clinical benefit.
  • Are greater than or equal to 18 years of age.
  • AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Total bilirubin ≤ ULN
  • Creatinine ≤ 1.5 x ULN
  • Absolute neutrophil count ≥ 1500 cells/mm3
  • Platelets ≥ 100,000/mm3
  • Hemoglobin ≥ 9.0 g/dL
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Agree to use effective contraceptive methods prior to study entry, during study participation, and for at least 30 days after the last administration of study medication.
  • Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, and agree to return for the required assessments.

Exclusion Criteria:

  • Women who are pregnant or nursing.
  • Have received radiotherapy or chemotherapy less than two weeks prior to first dose of study medication and have not recovered from all acute toxicities from prior treatments.
  • Have participated in any clinical trial involving conventional or investigational drugs within 28 days prior to initiation of ENMD-2076 dosing.
  • Have active, acute, or chronic clinically significant infections.
  • Have uncontrolled severe hypertension or congestive heart failure.
  • Have active angina pectoris or recent myocardial infarction (within 6 months).
  • Have chronic atrial fibrillation or QTc of greater than 470 msec.
  • Have had major surgery within 21 days of starting therapy.
  • Have planned surgical treatment of tumor(s)
  • Have additional uncontrolled serious medical or psychiatric illness.
  • Have any medical condition that would impair the administration of oral agents including significant bowel resection, inflammatory bowel disease or uncontrolled nausea or vomiting.
  • Have a 2+ protein by urinalysis or a history of nephrotic syndrome.
  • Known central nervous system metastasis.
  • Have history of deep vein thrombosis or pulmonary embolus, unless they are receiving therapeutic anticoagulation with warfarin or low-molecular-weight heparin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00658671

United States, Colorado
University of Colorado Hospital
Aurora, Colorado, United States, 80045
United States, Massachusetts
Dana Farber/Harvard Cancer Center
Boston, Massachusetts, United States
Sponsors and Collaborators
CASI Pharmaceuticals, Inc.
Study Director: William Gannon, MD, MBA CASI Pharmaceuticals, Inc.
  More Information

Responsible Party: CASI Pharmaceuticals, Inc. Identifier: NCT00658671     History of Changes
Other Study ID Numbers: 2076-CL-001
Study First Received: April 11, 2008
Last Updated: January 26, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Neoplasms processed this record on August 21, 2017